Drug firm Zydus Cadila today said it has received the final approval from the US health regulator to market desvenlafaxine extended release tablets, used to treat depression.
The approval from the United States Food and Drug Administration (US FDA) is to market desvenlafaxine extended release in the strengths of 50 mg and 100 mg, Zydus Cadila said in a BSE filing.
The drug will be manufactured at the group's formulations manufacturing facility at Moraiya in Ahmedabad, it added.
The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Shares of Cadila Healthcare, the company's listed entity, were today trading 1.41 per cent higher at Rs 498.30 per scrip in the afternoon trade on BSE.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)